Literature DB >> 33123905

Anti-inflammatory Activity of Mollugin on DSS-induced Colitis in Mice.

Juan Li1, Jin-Ling Zhang2, Xue-Peng Gong1, Meng Xiao1, Yuan-Yuan Song1, Hui-Fang Pi3, Guang Du4.   

Abstract

We aimed to explore the anti-inflammatory activity of mollugin extracted from Rubia cordifolia L, a traditional Chinese medicine, on dextran sulfate sodium (DSS)-induced ulcerative colitis (UC) in mice. Thirty C57BL/6 mice were divided into a control group (n=6), a model group (n=6), and three experimental groups (40, 20, 10 mg/kg of mollugin, n=6 each). DSS solution (3%) was given to mice in the model group and experimental groups from day 4 to day 10 to induce the mouse UC model. Mice in the experimental groups were intragastrically administrated mollugin from day 1 to day 10. Animals were orally given distilled water in the control group for the whole experiment time and in the model group from day 1 to day 3. The changes in colon pathology were detected by hematoxylin and eosin (HE) staining. Interleukin-1β (IL-1β) in the serum, and tumor necrosis factor-α (TNF-α) and interferon-γ (IFN) in the tissues were measured by enzyme linked immunosorbent assay. Expression levels of Toll-like receptor 4 (TLR4) and myeloid differentiation factor 88 in the colon tissues were detected by immunohistochemistry. Results showed that mollugin could significantly reduce weight loss and the disease activity index in the DSS-induced UC mouse model. HE examinations demonstrated that mollugin treatment effectively improved the histological damage (P<0.05). The overproduction of IL-1β and TNF-α was remarkably inhibited by mollugin treatment at doses of 20 and 40 mg/kg (P<0.05). Additionally, the levels of TLR4 in colon tissues were significantly reduced in mollugin-treated groups compared with the DSS group. Our findings demonstrated that mollugin ameliorates DSS-induced UC by inhibiting the production of pro-inflammatory chemocytokines.

Entities:  

Keywords:  DSS-induced colitis; anti-inflammatory activity; mollugin

Mesh:

Substances:

Year:  2020        PMID: 33123905     DOI: 10.1007/s11596-020-2262-5

Source DB:  PubMed          Journal:  Curr Med Sci        ISSN: 2523-899X


  4 in total

Review 1.  Current evidence supporting mucosal healing and deep remission as important treatment goals for inflammatory bowel disease.

Authors:  Guillaume Pineton de Chambrun; Pierre Blanc; Laurent Peyrin-Biroulet
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2016-04-18       Impact factor: 3.869

2.  MiR-146a regulates the development of ulcerative colitis via mediating the TLR4/MyD88/NF-κB signaling pathway.

Authors:  J-P Wang; L-N Dong; M Wang; J Guo; Y-Q Zhao
Journal:  Eur Rev Med Pharmacol Sci       Date:  2019-03       Impact factor: 3.507

3.  Gingko biloba extract (Ginaton) ameliorates dextran sulfate sodium (DSS)-induced acute experimental colitis in mice via reducing IL-6/STAT3 and IL-23/IL-17.

Authors:  Yan Sun; Lian-Jie Lin; Yan Lin; Li-Xuan Sang; Min Jiang; Chang-Qing Zheng
Journal:  Int J Clin Exp Med       Date:  2015-10-15

4.  Comprehensive analysis of intestinal cytokine messenger RNA profile by real-time quantitative polymerase chain reaction in patients with inflammatory bowel disease.

Authors:  Yoshinori Sawa; Nobuhide Oshitani; Kenji Adachi; Kazuhide Higuchi; Takayuki Matsumoto; Tetsuo Arakawa
Journal:  Int J Mol Med       Date:  2003-02       Impact factor: 4.101

  4 in total
  3 in total

1.  Phytochemical Characterization, Antioxidant and Anti-Proliferative Properties of Rubia cordifolia L. Extracts Prepared with Improved Extraction Conditions.

Authors:  Ravikiran B Humbare; Joyita Sarkar; Anjali A Kulkarni; Mugdha G Juwale; Sushil H Deshmukh; Dinesh Amalnerkar; Manohar Chaskar; Maria C Albertini; Marco B L Rocchi; Swapnil C Kamble; Seeram Ramakrishna
Journal:  Antioxidants (Basel)       Date:  2022-05-20

Review 2.  The Communication Between Intestinal Microbiota and Ulcerative Colitis: An Exploration of Pathogenesis, Animal Models, and Potential Therapeutic Strategies.

Authors:  Yu Hu; Zhen Ye; Mingquan Wu; Yingqi She; Linzhen Li; Yujie Xu; Kaihua Qin; Zhipeng Hu; Maoyi Yang; Fating Lu; Qiaobo Ye
Journal:  Front Med (Lausanne)       Date:  2021-12-13

Review 3.  A comprehensive review of Rubia cordifolia L.: Traditional uses, phytochemistry, pharmacological activities, and clinical applications.

Authors:  Min Wen; Qi Chen; Wang Chen; Jing Yang; Xiaogang Zhou; Chunxiang Zhang; Anguo Wu; Jia Lai; Jianping Chen; Qibing Mei; Shuo Yang; Cai Lan; Jianming Wu; Feihong Huang; Long Wang
Journal:  Front Pharmacol       Date:  2022-09-09       Impact factor: 5.988

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.